Pipeline
Therapeutics
| Program | Modality | target | Indication | Discovery | Pre-clinical | Phase I/II | Phase II/III | Partnership |
|---|---|---|---|---|---|---|---|---|
|
Antisense Oligonucleotides
|
ASO |
miR-485-3p |
AD, ALS, PD |
|
||||
|
miR-*** |
Epilepsy |
|
 |
|||||
|
mRNA |
GBM & Solid tumor |
|
||||||
|
Pre-mRNA |
SCA3 |
|
||||||
*GBM: Glioblastoma multiforme / SCA3: Spinocerebellar ataxia type 3
| ProgRAM | PROGRAM TARGET | ||
|---|---|---|---|
|
BMD-001 (BDDS: miR-485-3p ASO) |
microRNA-485-3p |
||
DISEASE INDICATION |
DEVELOPMENT STAGE |
||
|
AD, PD and ALS |
Pre-clinical |
||
SUMMARY |
|||
|
The microRNA-485-3p is responsible for lysosomal function, glial biology, and cellular homeostasis by regulating CD36, SIRT1 and PGC1 alpha. Overexpression of this molecule lead to deficiency of targe proteins, CD36, SIRT1 and PGC1 alpha and cause neurodegeneration and neuroinflammation in the brain. BMD-001 (or BDDS : miR-485-3p ASO) is an Antisense oligonucleotides encapsulated with proprietary Brain polymer to cross the blood-brain barrier and plasma membrane of microglia, astrocyte and neuron to degrade the microRNA 485-3p and treat neuroinflammation and neurodegeneration. |
|||
Diagnostics
| Medical Device | Program | IVD-USE | SIT | IIT | MFDS Approval | FDA Approval |
|---|---|---|---|---|---|---|
|
Detection kit |
miRStra |
Alzheimer's disease screening |
|
|
||
|
miRStra |
Alzheimer's disease biomarker |
|
|
|||
|
miRStra |
Amyotrophic lateral sclerosis biormarker |
|
|